Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Repertoire Immune Medicines
This is a phase 1/2, open-label, first-in-human, multi-center study to characterize the safety and tolerability of RPTR-168 administered i.v. as a monotherapy in patients with relapsed/refractory metastatic or locally-advanced HPV-16 E6/E7 positive tumors and melanoma. The study will include 2 dosing periods: A Dose Escalation (Phase 1) followed by an Expansion (Phase 2).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted